Alan Green talks Blue Prism #PRSM, Shell #RDSB, Braveheart Investments #BRH & Tiziana Life Sciences #TILS on Vox Markets podcast. 1 hour 12 minutes in.
Continue readingTiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ”It makes a lot of sense”, he says. Shailubhai says he’s pleased he’s covered this approach in his recent patent and in fact was one of the first to do it . ”COVID-19 grows in lungs, that’s where it proliferates and produces inflammation .. that leads to what’s known as…
Continue readingTHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue…
Continue readingTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : TIZIANA LIFE SCIENCES PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer…
Continue readingAlan Green discusses Barclays #BARC, BP #BP, Tiziana Life Sciences #TILS & Versarien #VRS with Jonathan Roy on the UK Investor Magazine podcast.
Continue readingTiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic option for COVID-19 patients. New York/London – April 27, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that…
Continue readingNew York/London – April 24, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it pursuant to an asset purchase agreement it has acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a. Dactinomycin), from Rasna Therapeutics, Inc. (“Rasna”) to expand its pipeline for a consideration of an initial…
Continue readingAlan Green and Zak Mir, Share Talk‘s resident chartist, discuss today’s announcement from Open Orphan Plc #ORPH involving it’s London-based subsidiary HVIVO , plus Tiziana Life Sciences #TILS and it’s TZLS-501 anti IL6 treatment for #COVID1 patients with chronic respiratory conditions, plus Bidstack #BIDS unique platform to serve ads into the huge online gaming market. Link on the image to view. #podcast #disruptive #podcasting #sharetalk
Continue readingLondon, New York, 24 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued a total of 6,118,797 ordinary shares of 3 pence each (“Ordinary Shares”) credited as fully paid in respect of (i) the conversion of…
Continue readingAlan Green discusses Braveheart Investments #BRH, Tiziana Life Sciences #TILS, Cadence Minerals #KDNC & ECR Minerals #ECR with Justin Waite on Vox Markets podcast. Interview is 39 minutes in.
Continue reading
